Medicinal chemistry design principles for liver targeting through OATP transporters

Current Topics in Medicinal Chemistry

Volumn 13, Issue 6 7, 2013, Pages 857-866

  Tu, Meihua ^a   Mathiowetz, Alan M ^a   Pfefferkorn, Jeffrey A ^a   Cameron, Kimberly O ^a   Dow, Robert L ^a   Litchfield, John ^a   Di, Li ^a   Feng, Bo ^a   Liras, Spiros ^a  

^a PFIZER INC   (United States)

Author keywords

Clearance; Fraction of absorbed; Lipophilicity; Liver selectivity; Liver targeting; Organic anion transporting poly peptide (OATP); Passive permeability; Tissue distribution; TissUe exposure; Tissue selectivity

Indexed keywords

ORGANIC ANION TRANSPORTER; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER MODEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG EXPOSURE; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG TARGETING; HEPATITIS; HUMAN; IONIZATION; LIPOPHILICITY; LIVER; LIVER CELL CARCINOMA; METABOLIC REGULATION; NONHUMAN; RAT; TISSUE DISTRIBUTION;

EID: 84878779623     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313070008     Document Type: Article

References (34)

1. Lin, J. H. Tissue distribution and pharmacodynamics: a complicated relationship. Curr. Drug. Metab. 2006, 7 (1), 39-65.
2. Lanao, J. M.; Fraile, M. A. Drug tissue distribution: study methods and therapeutic implications. Curr. Pharm. Des. 2005, 11 (29), 3829-3845.
3. Kahl, R., The Liver. In Toxicology, Marquardt, H., Ed. Academic Press: San Diego, CA, 1999; pp 273-296.
4. Pfefferkorn, J. A. 'Muscle-sparing' statins: preclinical profiles and future clinical use. Curr. Opin. Invest. Drugs 2009, 10 (3), 245-252.
5. von Geldern, T. W.; Tu, N.; Kym, P. R.; Link, J. T.; Jae, H. S.; Lai, C.; Apelqvist, T.; Rhonnstad, P.; Hagberg, L.; Koehler, K.; Grynfarb, M.; Goos-Nilsson, A.; Sandberg, J.; Osterlund, M.; Barkhem, T.; Höglund, M.; Wang, J.; Fung, S.; Wilcox, D.; Nguyen, P.; Jakob, C.; Hutchins, C.; Färnegårdh, M.; Kauppi, B.; Ohman, L.; Jacobson, P. B. Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. J. Med. Chem. 2004, 47 (17), 4213-4230.
6. Boyer, S. H.; Jiang, H.; Jacintho, J. D.; Reddy, M. V.; Li, H.; Li, W.; Godwin, J. L.; Schulz, W. G.; Cable, E. E.; Hou, J.; Wu, R.; Fujitaki, J. M.; Hecker, S. J.; Erion, M. D. Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J. Med. Chem. 2008, 51 (22), 7075-7093.
7. Bebernitz, G. R.; Beaulieu, V.; Dale, B. A.; Deacon, R.; Duttaroy, A.; Gao, J.; Grondine, M. S.; Gupta, R. C.; Kakmak, M.; Kavana, M.; Kirman, L. C.; Liang, J.; Maniara, W. M.; Munshi, S.; Nadkarni, S. S.; Schuster, H. F.; Stams, T.; Denny, I. S.; Taslimi, P. M.; Vash, B.; Caplan, S. L. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J. Med. Chem. 2009, 52 (19), 6142-6152.
8. Pfefferkorn, J. A.; Guzman-Perez, A.; Litchfield, J.; Aiello, R.; Treadway, J. L.; Pettersen, J.; Minich, M. L.; Filipski, K. J.; Jones C. S.; Tu, M.; Aspnes, G.; Risley, H.; Bian, J.; Stevens, B. D Bourassa, P.; D'Aquila, T.; Baker, L.; Barucci, N.; Robertson, A. S.; Bourbonais, F.; Derksen, D. R.; MacDougall, M.; Cabrera, O. Chen, J.; Lapworth, A. L.; Landro, J. A.; Zavadoski, W. J. Atkinson, K.; Haddish-Berhane, N.; Tan, B.; Yao, L.; Kosa, R. E. Varma, M. V.; Feng, B.; Duignan, D. B.; El-Kattan, A. F. Murdande, S.; Liu, S.; Ammirati, M.; Knafels, J.; Silva-Jardine, P. D.; Sweet, L.; Liras, S.; Rolph, T. P. Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus. J. Med. Chem. 2012, 55 (3), 1318-1333.
9. Lachance, N.; Guiral, S.; Huang, Z.; Leclerc, J.-P.; Li, C. S.; Oballa, R. M.; Ramtohul, Y. K.; Wang, H.; Wu, J.; Zhang, L. Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. Bioorg. Med. Chem. Lett. 2012, 22 (1), 623-627.
10. Oballa, R. M.; Belair, L.; Black, W. C.; Bleasby, K.; Chan, C. C.; Desroches, C.; Du, X.; Gordon, R.; Guay, J.; Guiral, S.; Hafey, M. J.; Hamelin, E.; Huang, Z.; Kennedy, B.; Lachance, N.; Landry, F.; Li, C. S.; Mancini, J.; Normandin, D.; Pocai, A.; Powell, D. A.; Ramtohul, Y. K.; Skorey, K.; Sørensen, D.; Sturkenboom, W.; Styhler, A.; Waddleton, D. M.; Wang, H.; Wong, S.; Xu, L.; Zhang, L. Development of a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor (MK-8245) to Establish a Therapeutic Window for the Treatment of Diabetes and Dyslipidemia. J. Med. Chem. 2011, 54 (14), 5082-5096.
11. Meijer, D. K.; Molema, G. Targeting of drugs to the liver. Semin. Liver Dis. 1995, 15 (3), 202-256.
12. Wu, J.; Nantz, M. H.; Zern, M. A. Targeting Hepatocytes for Drug and Gene delivery: Emerging Novel Approaches and Applications. Front. Biosci. 2002, 7, 717-725.
13. Lew, W.; Chen, X.; Kim, C. U. Discovery and Development of GS 4104 (oseltamivir): An Orally Active Influenza Neuraminidase Inhibitor. Curr. Med. Chem. 2010, 7 (6), 663-672.
14. Kusuhara, H.; Sugiyama, Y. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J. Controlled Release 2002, 78 (1-3), 43-54.
15. Abe, T.; Kakyo, M.; Tokui, T.; Nakagomi, R.; Nishio, T.; Nakai, D.; Nomura, H.; Unno, M.; Suzuki, M.; Naitoh, T.; Matsuno, S.; Yawo, H. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 1999, 274 (24), 17159-17163.
16. Konig, J.; Cui, Y.; Nies, A.; Keppler, D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. 2000, 275 (30), 23161-23168.
17. Niemi, M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007, 8 (7), 787-802.
18. Niemi, M.; Pasanen, M. K.; Neuvonen, P. J. Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacological Reviews 2011, 63 (1), 157-181.
19. Kullak-Ublick, G. A.; Ismair, M. G.; Stieger, B.; Landmann, L.; Huber, R.; Pizzagalli, F.; Fattinger, K.; Meier, P. J.; Hagenbuch, B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001, 120, 525-533.
20. Hagenbuch, B.; Meier, P. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004, 447, 653-665.
21. Varma, M. V. S.; Chang, G.; Lai, Y.; Feng, B.; El-Kattan, A. F.; Litchfield, J.; Goosen, T. C. Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion. Drug Metab. Dispos. 2012, 40 (8), 1527-1537.
22. Lai, Y. Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion. Expert Opin. Drug Metab. Toxicol. 2009, 5 (10), 1175-1187.
23. Yang, Y.; Engkvist, O.; Llinàs, A.; Chen, H. Beyond Size, Ionization State, and Lipophilicity: Influence of Molecular Topology on Absorption, Distribution, Metabolism, Excretion, and Toxicity for Druglike Compounds. J. Med. Chem. 2012, 55 (8), 3667-3677.
24. Gleeson, M. P. Generation of a Set of Simple, Interpretable ADMET Rules of Thumb. J. Med. Chem. 2008, 51 (4), 817-834.
25. Varma, M. V. S.; Obach, R. S.; Rotter, C.; Miller, H. R.; Chang, G.; Steyn, S. J.; El-Kattan, A.; Troutman, M. D. Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination. J. Med. Chem. 2010, 53 (3), 1098-1108.
26. Di, L.; Whitney-Pickett, C.; Umland, J. P.; Zhang, H.; Zhang, X.; Gebhard, D. F.; Lai, Y.; Federico, J. J.; Davidson, R. E.; Smith, R.; Reyner, E. L.; Lee, C; Feng, B.; Rotter, C; Varma, M. V.; Kempshall, S.; Fenner, K.; El-Kattan, A. F.; Liston, T. E.; Troutman, M. D. Development of a new permeability assay using low-efflux MDCKII cells. J. Pharm. Sci. 2011, 100 (11), 4974-4985.
27. Roth, M.; Obaidat, A.; Hagenbuch, B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br. J. Pharmacol. 2012,165 (5), 1260-1287.
28. Balogh, G. T.; Tarcsay, A.; Keseru, G. M. Comparative evaluation of pKa prediction tools on a drug discovery dataset. J. Pharm. Biomed. Anal. 2012, 67-68, 63-70.
29. Gupta, R. R.; Gifford, E. M.; Liston, T.; Waller, C. L.; Hohman, M.; Barry A. Bunin; Ekins, S. Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties. Drug Metab. Dispos. 2010, 38 (11), 2083-2090.
30. Karlgren, M.; Vildhede, A.; Norinder, U.; Wisniewski, J. R.; Kimoto, E.; Lai, Y.; Haglund, U.; Artursson, P. Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug-Drug Interactions. J. Med. Chem. 2012, 55 (10), 4740-4763.
31. Sherer, E. C; Verras, A.; Madeira, M.; Hagmann, W. K.; Sheridan, R. P.; Roberts, D.; Bleasby, K.; Cornell, W. D. QSAR Prediction of Passive Permeability in the LLC-PK1 Cell Line: Trends in Molecular Properties and Cross Prediction of Caco-2 Permeabilities. Mol. Inf. 2012, 31, 231-245.
32. Tantishaiyakul, V. Prediction of Caco-2 cell permeability using partial least square multivariate analysis. Pharmazie 2001, 56, 407-411.
33. Fujikawaa, M.; Nakaob, K.; Shimizub, R.; Akamatsua, M. QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorganic & Medicinal Chemistry Letters 2007, 15 (11), 3756-3767.
34. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43 (20), 3714-3717.